Search NLS News

Up until recently the road for people suffering from obesity to lose weight was long and hard, often impossible, but a new breakthrough drug from Denmark has led to a paradigm shift. Worldwide obesity has tripled since 1975, according to the World Health Organization (WHO), and the World Obesity Federation estimates that there are 1.1 […]

Professor Jens Juul Holst has made discoveries that have strongly influenced how people with obesity or type 2 diabetes are treated today. Throughout a long career, this internationally recognized researcher has put gut hormones on the world map and helped to make discoveries that enable millions of people to be treated for type 2 diabetes […]

SynAct Pharma has announced that Björn Westberg has been appointed Chief Financial Officer and member of the management team at SynAct. “I’m excited at the opportunity to join SynAct at such an important time in its development,” says Björn Westberg. “The SynAct team has accomplished a lot over the past several years from joining the […]

The company will use the financing to expand and commercialize its self-sampling technology for remote healthcare solutions and personalized medicine. The funding will be used to increase production capacity, develop new products, and intensify sales and marketing efforts. The investment round was led by Sciety and the network Sciety Venture Partners. Sciety and its network […]

Umeå based HiloProbe has entered a partnership with the major international company Biocartis Group. This is a strategically important step for HiloProbe in their aim to reach out globally with its colorectal cancer test-product, ColoNode, they state. “We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus […]

Ultomiris has been approved in the European Union as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). “Just four years since delivering the first approved NMOSD treatment to the EU, we are pleased to once again advance the treatment […]

The first patient has been dosed in a Phase I trial of TILT Biotherapeutics’ oncolytic adenovirus TILT-123. The multi-centre open-label, phase I, dose-escalation trial will evaluate igrelimogene litadenorepvec (TILT-123) in combination with avelumab in squamous cell carcinoma of head and neck (SCCHN), and melanoma in patients with advanced solid tumors refractory to, or progressing after, […]

Philip Siberg has replaced Pia Renaudin who has been the CEO of Senzime since February 2019. Philip Siberg has been Chairman of Senzime since 2016, when the company acquired Acacia Designs, which he was the CEO of. Acacia Designs pioneered the development of the TetraGraph system based on research from Mayo Clinic in the USA, […]

Alligator Bioscience has announced that Orion Corporation has selected bispecific lead antibodies and is exercising its option to develop these molecules under the existing research collaboration and license agreement between the two companies. Alligator will continue to generate additional data in order for Orion to select the final development candidate over the coming months. Upon […]

SmartCella Holding has announced that Niklas Prager has been appointed as the new CEO. “Niklas has a perfect background for SmartCella. He has experience from the global pharma industry and has also led projects that fundamentally transformed pharmaceutical companies through creative ideas and great determination. With Niklas as CEO, we intend to accelerate our expansion, […]